Funding
Funding not disclosed
Founders
Product
Problem
Current vaccines primarily target viral antigens, potentially limiting their effectiveness against mutations and new viruses. This approach may require frequent updates and may not provide broad protection against emerging threats.
Solution
RUTI Immune is developing a vaccine that enhances trained innate immunity, offering a broader defense against both existing and novel viruses. By focusing on strengthening the body's first line of defense, the vaccine aims to provide a more adaptable and longer-lasting protection compared to traditional antigen-based vaccines. This approach allows for potential compatibility with existing vaccines and greater resilience against viral mutations. The company leverages the RUTI vaccine technology, originally developed by Archivel Farma, to create a universal vaccine platform.
Target Audience
The primary target audience includes individuals seeking broad protection against viral infections, as well as healthcare providers and public health organizations looking for adaptable vaccine solutions.
Features
- Enhances trained innate immunity for broad-spectrum viral protection
- Designed for compatibility with existing antigen-based vaccines
- Adaptable to viral mutations and emerging viruses
- Based on the RUTI vaccine technology